Re: Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

被引：17
作者：
Di Maio, Massimo [1 ]
Daniele, Bruno [2 ]
Gallo, Ciro [3 ]
Perrone, Francesco [1 ]
机构：
[1] Natl Canc Inst, Clin Trials Unit, Naples, Italy
[2] G Rummo Hosp, Oncol Unit, Benevento, Italy
[3] Univ Naples 2, Dept Med & Publ Hlth, Naples, Italy
来源：
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2008年 / 100卷 / 21期
关键词：
D O I：
10.1093/jnci/djn341
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 7 条
  • [1] Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis?
    Abou-Alfa, G. K.
    Amadori, D.
    Santoro, A.
    Figer, A.
    De Greve, J.
    Lathia, C.
    Voliotis, D.
    Anderson, S.
    Moscovici, M.
    Ricci, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] False positive rates of randomized Phase II designs
    Liu, PY
    LeBlanc, M
    Desai, M
    [J]. CONTROLLED CLINICAL TRIALS, 1999, 20 (04): : 343 - 352
  • [3] Sorafenib in advanced hepatocellular carcinoma
    Llovet, Josep M.
    Ricci, Sergio
    Mazzaferro, Vincenzo
    Hilgard, Philip
    Gane, Edward
    Blanc, Jean-Frederic
    Cosme de Oliveira, Andre
    Santoro, Armando
    Raoul, Jean-Luc
    Forner, Alejandro
    Schwartz, Myron
    Porta, Camillo
    Zeuzem, Stefan
    Bolondi, Luigi
    Greten, Tim F.
    Galle, Peter R.
    Seitz, Jean-Francois
    Borbath, Ivan
    Haussinger, Dieter
    Giannaris, Tom
    Shan, Minghua
    Moscovici, Marius
    Voliotis, Dimitris
    Bruix, Jordi
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) : 378 - 390
  • [4] Design and endpoints of clinical trials in hepatocellular carcinoma
    Llovet, Josep M.
    Di Bisceglie, Adrian M.
    Bruix, Jordi
    Kramer, Barnett S.
    Lencioni, Riccardo
    Zhu, Andrew X.
    Sherman, Morris
    Schwartz, Myron
    Lotze, Michael
    Talwalkar, Jayant
    Gores, Gregory J.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (10): : 698 - 711
  • [5] MILLER AA, 2007, J CLIN ONCOL, V25, P3538
  • [6] Design issues of randomized phase II trials and a proposal for phase II screening trials
    Rubinstein, LV
    Korn, EL
    Freidlin, B
    Hunsberger, S
    Ivy, SP
    Smith, MA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 7199 - 7206
  • [7] NEW DESIGNS FOR THE SELECTION OF TREATMENTS TO BE TESTED IN RANDOMIZED CLINICAL-TRIALS
    SIMON, R
    THALL, PF
    ELLENBERG, SS
    [J]. STATISTICS IN MEDICINE, 1994, 13 (5-7) : 417 - 429
1